Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
Anthony R. Mato(Abramson Center for Jewish Life), Brian T. Hill(Cleveland Clinic), Nicole Lamanna(Columbia University Irving Medical Center), Paul M. Barr(Cancer Institute (WIA)), Chaitra S. Ujjani(Georgetown University), Danielle M. Brander(Duke Medical Center), Cullan Howlett(Rutgers, The State University of New Jersey), Alan P Skarbnik(Hackensack University Medical Center), Bruce D. Cheson(Georgetown University), Clive S. Zent(Cancer Institute (WIA)), Jeffrey J. Pu(Penn State Milton S. Hershey Medical Center), Pavel Kiselev(Bristol-Myers Squibb (Switzerland)), Kenneth A. Foon(Bristol-Myers Squibb (Switzerland)), Jonas Lenhart(Bristol-Myers Squibb (Switzerland)), Spencer Henick Bachow(Columbia University Irving Medical Center), Allison Winter(Cleveland Clinic), Allan-Louie Cruz(MedStar Washington Hospital Center), David F. Claxton(Penn State Milton S. Hershey Medical Center), André Goy(Hackensack University Medical Center), Catherine Daniel(Abramson Center for Jewish Life), Krista M. Isaac(Abramson Center for Jewish Life), Kaitlin Kennard(Abramson Center for Jewish Life), Colleen Timlin(Abramson Center for Jewish Life), Molly Fanning(Abramson Center for Jewish Life), L. Gashonia(Abramson Center for Jewish Life), Melissa Yacur(Penn State Milton S. Hershey Medical Center), Jakub Svoboda(Abramson Center for Jewish Life), Stephen J. Schuster(Abramson Center for Jewish Life), Chadi Nabhan(Cardinal Health (United States))
Cited by 221Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis